UK DOCTORS JOIN PROTEST AGAINST ICI

17 May 1992

More than 300 doctors in the UK have said they will support the protest organized by the environmental group Greenpeace against Imperial Chemical Industries' continuing production of ozone-depleting chlorofluorocarbons (CFCs). ICI is reportedly responsible for 50%-60% of the UK's total CFC output.

Greenpeace has sent letters to over 4,000 general practitioners listing the drugs produced by ICI, as well as alternatives produced by other companies, although the organization has stressed that GPs should not alter treatment in patients already maintained on ICI products.

ICI has responded to the protest by pointing out that it is well ahead of the rest of Europe in its plans to phase out CFC-based products. This timescale involves an 85% reduction by 1993 and complete cessation by 1995, according to the company, and compares favorably with a European Community directive which sets the date for cessation as 1997.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight